Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory ...

Akeso has a validated process in place for developing antibodies but does require US exposure to meet its lofty valuation.

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...

Industry analyst GlobalData has highlighted the significance of US pharma major Merck's (NYSE: MRK) plan to buy US biotech ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has ...

Global Biotech is surging as policy fears fade and innovation takes centre stage. Here’s what’s driving the comeback into ...

Researchers advance mRNA cancer therapies as France tests new methods, while the FDA approves Bayer’s Hyrnuo for HER2-mutated ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Layoff filings show UnitedHealth’s Optum units planning the largest set of early-2026 job reductions among major healthcare ...

Over the past two years, Merck ( MRK 0.19%) has faced several challenges, resulting in a decline in the company's share price ...

New Jersey’s pharma sector faces new layoffs as Merck cuts 204 jobs and Bristol Myers Squibb plans 110 reductions amid ...